VC-backed Prevail Therapeutics beefs up board with new addition
New York City-based Prevail Therapeutics Inc, a developer of gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, has named Dr. Francois Nader to its board of directors. Nader was the president, CEO and executive director of NPS Pharma. The investors included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.
25 May 2018•3 mins read
